| Literature DB >> 28058055 |
Xiang-Lin Yang1, Yuan Zhou2, Xin-Ling Liu2.
Abstract
A series of structurally related 2,4-dioxopyrimidine-1-carboxamide derivatives as highly potent inhibitors against acid ceramidase were subjected to hologram quantitative structure-activity relationship (HQSAR) analysis. A training set containing 24 compounds served to establish the HQSAR model. The best HQSAR model was generated using atoms, bond, connectivity, donor and acceptor as fragment distinction and 3-6 as fragment size with six components showing cross-validated q2 value of 0.834 and conventional r2 value of 0.965. The model was then employed to predict the potency of test set compounds that were excluded in the training set, and a good agreement between the experimental and predicted values was observed exhibiting the powerful predictable capability of this model [Formula: see text]. Atom contribution maps indicate that the electron-withdrawing effects at position 5 of the uracil ring, the preferential acyl substitution at N3 position and the substitution of eight-carbon alkyl chain length at N1 position predominantly contribute to the inhibitory activity. Based upon these key structural features derived from atom contribution maps, we have designed novel inhibitors of acid ceramidase possessing better inhibitory activity.Entities:
Keywords: Acid ceramidase; Drug design; Hologram QSAR; Inhibitors
Year: 2016 PMID: 28058055 PMCID: PMC5175217
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Chemical structures, experimental and predicted activities, and residuals of compounds included in the training set and test set.
|
|
t test set compounds
HQSAR analysis for the effect of various fragment distinction combinations on the key statistical parameters using default fragment size (4-7
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | A/B | 0.950 | 0.248 | 0.770 | 0.536 | 307 | 5 |
| 2 | A/B/C | 0.865 | 0.388 | 0.711 | 0.569 | 83 | 3 |
| 3 | A/B/C/H | 0.865 | 0.388 | 0.711 | 0.569 | 83 | 3 |
| 4 | A/B/H | 0.950 | 0.248 | 0.770 | 0.536 | 307 | 5 |
| 5 | A/B/DA | 0.914 | 0.318 | 0.767 | 0.524 | 353 | 4 |
| 6 | A/B/C/DA | 0.946 | 0.267 | 0.824 | 0.481 | 257 | 6 |
| 7 | A/B/H/DA | 0.914 | 0.318 | 0.767 | 0.524 | 353 | 4 |
| 8 | A/B/C/H/DA | 0.946 | 0.267 | 0.824 | 0.481 | 257 | 6 |
q2, cross-validated correlation coefficient; SEP, cross-validated standard error; r2, noncross-validated correlation coefficient; SEE, non cross-validated standard error; HL, hologram length; N, optimal number of components. Fragment distinction: A, atoms; B, bonds; C, connections; H, hydrogen atoms; DA, donor and acceptor.
The model chosen for analysis is highlighted in bold fonts.
HQSAR analysis for the influence of various fragment size using the best fragment distinction (A/B/C/DA). The model chosen for analysis is highlighted in bold fonts
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 1-3 | 0.892 | 0.348 | 0.725 | 0.555 | 401 | 3 |
| 4-7 | 0.946 | 0.267 | 0.824 | 0.481 | 257 | 6 |
| 3-10 | 0.933 | 0.298 | 0.721 | 0.606 | 353 | 6 |
| 1-4 | 0.912 | 0.315 | 0.781 | 0.495 | 83 | 3 |
| 2-5 | 0.934 | 0.272 | 0.807 | 0.466 | 151 | 3 |
| 3-6 | 0.965 | 0.214 | 0.834 | 0.468 | 257 | 6 |
| 5-8 | 0.939 | 0.283 | 0.762 | 0.560 | 353 | 6 |
| 6-9 | 0.934 | 0.295 | 0.740 | 0.585 | 353 | 6 |
| 7-10 | 0.927 | 0.309 | 0.736 | 0.589 | 353 | 6 |
Figure 1Plot of experimental versus predicted pIC50 values of the training set and test set molecules
Figure 2Atomic contribution maps for compounds 32, 30, 21 and compound 25
Figure 3Structures of designed compounds with potentially improved biological activity
Chemical structures of designed molecules and predicted biological activities
|
|